In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Chiesi plans to take complete ownership of Cornerstone; finalized

Executive Summary

Italian drug company Chiesi Farmaceutici SPA has proposed to acquire the remaining 40% of publicly traded spec pharma Cornerstone Therapeutics Inc. that it doesn’t already own for $6.40-6.70 in cash per share (a 21% premium on the midpoint), valuing the deal as high as $70.9mm. Cornerstone has put together a five-member special committee to review the offer.
Deal Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Payment Includes Cash
    • Partial Acquisition
    • Includes Contract

Related Companies

Advertisement
UsernamePublicRestriction

Register